Cargando…
Computational Approaches for Supporting Combination Therapy in the Post-Aducanumab Era in Alzheimer’s Disease
With the approval of aducanumab on the “Accelerated Approval Pathway” and the recognition of amyloid load as a surrogate marker, new successful therapeutic approaches will be driven by combination therapy as was the case in oncology after the launch of immune checkpoint inhibitors. However, the shee...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
IOS Press
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673549/ https://www.ncbi.nlm.nih.gov/pubmed/34966890 http://dx.doi.org/10.3233/ADR-210039 |